Related Experiment Video

Updated: Feb 21, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K

Investigating Oral Absorption of Carbamazepine in Pediatric Populations

Philip Kohlmann1, Cordula Stillhart1, Martin Kuentz2

  • 1Formulation Research & Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

The AAPS Journal
|October 4, 2017
PubMed

Insights

Predicting oral drug absorption in children requires understanding age-related physiological changes. This study used physiologically based pharmacokinetic (PBPK) models to assess carbamazepine absorption in pediatric populations, highlighting key factors for improved drug efficacy and safety.

Area of Science:

  • Pharmacokinetics
  • Pediatric Pharmacology
  • Drug Absorption Modeling

Background:

  • Optimizing pediatric medicine efficacy and safety necessitates accurate pharmacokinetic predictions.
  • Physiologically based pharmacokinetic (PBPK) models offer potential but face challenges due to knowledge gaps in pediatric physiological development.

Purpose of the Study:

  • To investigate age-dependent differences in oral absorption of carbamazepine (CBZ) in neonates, infants, and children.
  • To develop and validate a PBPK model for predicting oral drug absorption across pediatric age groups.

Main Methods:

  • Developed an oral absorption model in GastroPlus® for carbamazepine.
  • Extrapolated an adult PBPK model to pediatric populations, validating with clinical data.
  • Performed sensitivity analyses on uncertain parameters and in vitro dissolution testing.

Main Results:

  • Age-based scaling of physiological parameters, especially clearance, is crucial for accurate PBPK simulations in children.
  • Carbamazepine absorption is sensitive to solubility, particle radius, and intestinal transit time, varying by pediatric age group and dose.
  • In vitro dissolution testing in pediatric biorelevant media showed minimal age-dependent changes in dissolution kinetics.

Conclusions:

  • Understanding age-dependent oral absorption is vital for improving drug exposure predictions in pediatric patients.
  • PBPK modeling, when refined with age-specific physiological data, enhances confidence in pediatric oral biopharmaceutical tools.
  • Further research into pediatric physiological factors influencing drug absorption is warranted.

Keywords:
BCS2PBPK modelingin vitro dissolutionoral absorptionpediatric biopharmaceutics

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.7K
Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution09:59

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

18.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
351
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
354
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
829